Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-06-21
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotechnology company using its Recursion OS platform, automated labs, and proprietary data to discover and develop medicines internally and with partners.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Must Unlock the AI Drug Engine
The upside depends less on having more AI tools and more on proving that the integrated lab-data-model stack can repeatedly create human outcomes. One credible registration path plus steadier partner economics could justify a meaningful rerating by 2031.

Analysis

Thesis
Recursion is a leveraged bet that AI makes hypothesis generation cheap while proprietary wet-lab data, automated experimentation, and downstream drug rights stay scarce; if 2026-2028 clinical proof broadens beyond one program, the stock can rerate from cash-backed skepticism to a hybrid platform biotech with multiple monetization paths.
Last Economy Alignment
Recursion benefits from cheaper cognition because it owns the scarce layer that AI alone cannot copy: proprietary data, automated labs, and drug rights. The cap on the score is that value still must pass through human biology, trials, and regulators.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
This is a proof-driven rerating case, not a pure volume case. If Recursion gets one credible late-stage or commercial path from its owned pipeline, adds a second internal translation win, and makes partner economics more recurring, investors can reasonably value it as more than a cash-funded option on AI drug discovery. I am not underwriting software-style economics; I am underwriting a better quality mix of assets, validation, and capital efficiency.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is validation, not imagination. Recursion already has the platform, data, and automation base; what it still must prove is that these assets repeatedly create clinically relevant outcomes fast enough to improve partner economics and outrun dilution. Regulatory path clarity, partner milestone cadence, controls remediation, and burn discipline matter because they determine whether the market eventually pays for a real engine or keeps valuing an expensive option.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.43
They control a hard-to-copy loop of proprietary lab data, automated experiments, and drug rights, so cheaper AI can make their engine more productive. The risk is that faster discovery still has to survive biology and regulators, and that is where the proof burden sits.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$6.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case